Team-Based Approach Essential in HCC Care
May 13th 2020The implementation of a multidisciplinary team, which has demonstrated a marked survival advantage compared with single-provider care, is critical in hepatocellular carcinoma (HCC), particularly as it relates to the evolving role of radiation, surgical resection, liver transplantation, and systemic treatment, explained Neehar Parikh, MD.
Locoregional Treatments Still Key in HCC Care
May 11th 2020A number of treatment options exist for patients with localized hepatocellular carcinoma (HCC), including surgical resection, transplantation, ablation, stereotactic body radiotherapy (SBRT), and embolization, said Riad Salem, MD, who added that a multidisciplinary team is needed to determine the optimal use of these approaches among newer novel systemic treatments.
HCC Treatment Continues to Improve, But Biomarkers Are Still Needed
March 14th 2020A flood of targeted therapy and immunotherapy options to both the first- and second-line settings of hepatocellular carcinoma (HCC) has had significant implications on the treatment of patients in this space and will likely create challenges regarding sequencing, said Richard S. Finn, MD.
Individualized Treatment Is Key for mCRC
March 5th 2020Key elements that should inform treatment decisions for patients with metastatic colorectal cancer (mCRC) include molecular profiling, tumor sidedness, and microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) status, according to Michael J. Overman, MD.
Combination Therapy Bests Standard of Care in BRAF+ CRC
January 28th 2020Encorafenib (Braftovi) plus cetuximab (Erbitux) with or without binimetinib (Mektovi) demonstrated longer maintenance of quality of life (QoL) on patient-reported assessments over current standard of care in the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.
Surufatinib Improves Outcomes in Advanced Pancreatic NETs
January 23rd 2020Surufatinib improved progression-free survival (PFS) compared with placebo in patients with low- or intermediate-grade advanced pancreatic neuroendocrine tumors (pNETs) for whom there is no effective therapy, according to a preplanned interim analysis of the phase III SANET-p trial (NCT02589821) that was completed by an independent data monitoring committee (IDMC).
PARP Inhibitor Provides Another Option for Metastatic Pancreatic Cancer
January 8th 2020The metastatic pancreatic cancer paradigm has expanded to include frontline maintenance therapy with the PARP inhibitor olaparib (Lynparza), as it recently received the green light from the FDA with a December 2019 approval.
Nurses Can Refer Patients to Reliable Stomach Cancer Information
September 4th 2019When one of your patients is diagnosed with gastrointestinal cancer, it can be difficult for them to cope with their diagnosis. However, as their Oncology nurse, you can help guide them to reliable patient resources on stomach cancer, like Debbie’s Dream Foundation.
Immunotherapy Combo Is Promising in MSI-H Colorectal Cancer
August 26th 2019The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer (mCRC) whose tumors are microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR)—a population with a historically poor prognosis, said Heinz-Josef Lenz, MD, FACP.
FDA Approves Bevacizumab Biosimilar for 5 Cancer Types
June 28th 2019The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.